For the topic of pathology cardiomyopathy

Asking for Preferences
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
Loading Image
Loading Image
Loading Image
I have comprehensive content and all three pathology images. Now I'll compile the complete study notes.

Pathology of Cardiomyopathy — Study Notes

Sources: Robbins & Kumar Basic Pathology (Robbins Pathology), Robbins Cotran & Kumar Pathologic Basis of Disease, Goldman-Cecil Medicine, Braunwald's Heart Disease

Overview

Cardiomyopathies are intrinsic cardiac muscle diseases that may be genetic or due to other well-defined causes. They are distinct from myocardial dysfunction secondary to ischaemic heart disease, valvular disease, hypertension, or congenital defects.
Three pathophysiologic categories:
TypeFrequencyCore DysfunctionLVEF
Dilated (DCM)~90%Systolic (contractile) dysfunction< 40%
Hypertrophic (HCM)Less commonDiastolic (relaxation) dysfunction50–80%
Restrictive (RCM)Least commonDiastolic (compliance) dysfunction25–50%
(ARVC and Takotsubo/Stress are additional recognised forms)
Robbins & Kumar Basic Pathology, p. 371 (Table 9.5)

1. Dilated Cardiomyopathy (DCM)

Definition & Epidemiology

Progressive cardiac dilation + contractile (systolic) dysfunction, usually with concurrent hypertrophy. The most common cardiomyopathy (~90% of cases).

Pathogenesis

Genetic causes (20–50% of cases)
  • 50 causative genes identified; autosomal dominant predominant
  • Loss-of-function mutations in cytoskeletal/sarcomeric proteins
  • Most common gene: TTN (titin) — truncating mutations in ~20–25% of familial DCM and 18% of sporadic cases
  • Other genes: β-myosin heavy chain, α-myosin heavy chain, cardiac troponin T, desmin (intermediate filament), nuclear lamins A/C
  • Lamin A/C mutations → arrhythmia + progressive AV conduction disease preceding DCM
  • X-linked DCM: dystrophin gene mutations (also causes Duchenne/Becker MD); accounts for 2–5% of familial cases
Key contrast: Gain-of-function mutations in sarcomere genes (β-MHC) → HCM; Loss-of-function mutations in same genes → DCM
Acquired causes
  • Viral myocarditis → coxsackievirus B, parvovirus B19, HHV-6, adenovirus; often leaves viral "footprints" in end-stage DCM
  • Alcohol/toxins: Alcohol + acetaldehyde direct cardiotoxicity → myocyte vacuolisation, mitochondrial abnormalities, fibrosis. Estimated threshold: ~6 drinks/day for 5–10 years. Abstinence improves >50%
  • Chemotherapy: Anthracyclines (doxorubicin, daunorubicin) — dose-dependent; risk at >450 mg/m²
  • Pregnancy (peripartum cardiomyopathy)
  • Iron overload, radiation, nutritional deficiency, cocaine, sarcoidosis, tachycardia-mediated

Morphology (Gross & Microscopic)

Gross: Four-chamber dilation and hypertrophy. Flabby, poorly contractile walls. Mural thrombus commonly at the LV apex (risk of embolism).
Microscopic (Masson trichrome): Myocyte hypertrophy + interstitial fibrosis (blue collagen on trichrome). Non-specific; no pathognomonic features at end stage.
DCM — Four-chamber dilation (A) with mural thrombus at LV apex (arrow). (B) Myocyte hypertrophy and interstitial fibrosis on Masson trichrome stain.
Fig. 9.25 — Robbins & Kumar Basic Pathology

Clinical Features

  • Symptoms of high pulmonary venous pressure (dyspnoea, orthopnoea, PND) or low cardiac output
  • Palpitations, presyncope, syncope (arrhythmias)
  • Advanced: sinus tachycardia, weak pulses, hypotension, elevated JVP, displaced apex
  • Complications: CHF, systemic/pulmonary emboli from mural thrombi, sudden cardiac death, AF

Management Principles

Heart failure therapy (ACE-I/ARB, beta-blockers, diuretics, aldosterone antagonists); ICD for arrhythmia; cardiac resynchronisation therapy; transplant in refractory cases.

2. Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

Definition

Autosomal dominant disorder characterised by right-sided heart failure and life-threatening ventricular arrhythmias, with a strong predilection for sudden cardiac death (SCD) in young athletes.

Epidemiology

  • Prevalence: 1 in 2000–5000 adults
  • Accounts for ~10% of sudden cardiac deaths in athletes

Pathogenesis

  • Mutations in desmosomal proteins at the intercalated disk — most commonly plakoglobin, plakophilin-2, desmoplakin, desmoglein-2, desmocollin-2
  • Also mutations in desmin (intermediate filament interacting with desmosome)
  • Mechanism: Desmosomal detachment → myocyte death (especially during strenuous exercise) → progressive replacement by fat and fibrosis

Morphology

Gross: Severely thinned RV free wall, markedly dilated RV. LV may be involved to a lesser extent in some cases.
Microscopic (Masson trichrome): RV myocardium focally replaced by fibro-fatty tissue — adipose tissue (white) and fibrous connective tissue (blue on trichrome).
ARVC — (A) Markedly dilated RV with near-transmural fibrofatty replacement of the free wall. (B) Masson trichrome showing replacement of myocardium (red) by fat and fibrous tissue (blue, arrow).
Fig. 9.26 — Robbins & Kumar Basic Pathology

Clinical Features

  • Palpitations, syncope, sudden cardiac death (often first presentation)
  • Ventricular tachycardia with LBBB morphology (origin in RV)
  • ECG: epsilon waves, T-wave inversions in V1–V3
  • Diagnosis: Task Force Criteria (imaging, ECG, histology, genetics, family history)

3. Hypertrophic Cardiomyopathy (HCM)

Definition

Massive myocardial hypertrophy without ventricular dilation, with preserved or hyperdynamic systolic function, but impaired diastolic filling. One-third have outflow tract obstruction (HOCM).

Pathogenesis

  • Gain-of-function mutations in sarcomeric proteins → hypercontractility → increased energy consumption → net negative energy balance
  • Autosomal dominant; >400 causative mutations in 9 genes
  • Top 3 genes (account for 70–80% of HCM):
    1. β-myosin heavy chain (MYH7) — most frequently involved
    2. Myosin-binding protein C (MYBPC3)
    3. Cardiac troponin T (TNNT2)
  • Same genes as DCM but mutations cause gain vs loss of function

Morphology

Gross:
  • Massive myocardial hypertrophy without ventricular dilation
  • 90%: Asymmetric septal hypertrophy (ASH) — septum thicker than LV free wall
  • Ventricular cavity → "banana-shaped" configuration on longitudinal section
  • Anterior mitral leaflet contacts the hypertrophied septum during systole → fibrous endocardial plaque in LVOT + SAM (systolic anterior motion)
  • Both atria dilated
Microscopic (H&E):
  • Marked myocyte hypertrophy
  • Myocyte/myofiber disarray — haphazard arrangement (pathognomonic)
  • Interstitial fibrosis
  • Characteristic branching of myocytes
HCM — (A) Asymmetric septal hypertrophy with "banana-shaped" LV lumen and fibrous plaque (arrow). (B) H&E showing classic myocyte disarray, hypertrophy, and interstitial fibrosis.
Fig. 9.27 — Robbins & Kumar Basic Pathology

Clinical Features

  • Typically manifests at postpubertal growth spurt
  • Exertional dyspnoea + harsh systolic ejection murmur (outflow obstruction)
  • Angina — due to massive hypertrophy + increased O₂ demand + compromised intramural coronary flow (even without CAD)
  • Murmur increases with Valsalva/standing (↓ preload → more obstruction)
  • Murmur decreases with squatting/leg raise (↑ preload)

Major Complications

ComplicationMechanism
Sudden cardiac deathVentricular fibrillation — #1 cause of SCD in athletes <35 years (1/3 of cases)
Atrial fibrillationLeft atrial dilation; risk of mural thrombus & stroke
Infective endocarditisMitral valve (turbulent flow)
Congestive heart failureChronic diastolic dysfunction

Management

  • Beta-blockers or calcium channel blockers (promote ventricular relaxation)
  • Avoid vasodilators, dehydration, intense exercise
  • ICD for high-risk SCD
  • Septal reduction: surgical myectomy or alcohol septal ablation
  • Mavacamten (myosin inhibitor) — reduces hypercontractility

4. Restrictive Cardiomyopathy (RCM)

Definition

Decreased ventricular compliance → impaired ventricular filling during diastole ("stiff ventricle"). The least common primary cardiomyopathy.

Pathogenesis & Causes

Primary:
  • Idiopathic (interstitial fibrosis)
Secondary (infiltrative/storage):
CauseKey Feature
Amyloidosis (most common systemic cause)AL type (light chains) or ATTR (transthyretin); ATTR common in elderly Black men (Val122Ile mutation)
SarcoidosisNon-caseating granulomas; also causes conduction defects and VT
HaemochromatosisIron deposition; responds to phlebotomy/chelation
Glycogen storage diseasesPompe disease, Fabry disease
Radiation fibrosisPost-radiotherapy interstitial fibrosis
MucopolysaccharidosesHurler, Hunter syndromes
Endomyocardial forms:
  • Endomyocardial fibrosis: Most common worldwide (tropical Africa); diffuse fibrosis of ventricular endocardium + sub-endocardium; affects tricuspid and mitral valves; linked to helminthic infections and nutritional deficiency
  • Loeffler endomyocarditis: Peripheral hypereosinophilia + eosinophilic tissue infiltrates; eosinophil granule products (major basic protein) → endocardial/myocardial necrosis → scarring → mural thrombus

Morphology

  • Gross: Ventricles of approximately normal size, cavities not dilated, myocardium firm; both atria typically dilated (due to restricted ventricular filling and pressure overload)
  • Microscopic: Variable interstitial fibrosis; endomyocardial biopsy reveals specific cause (amyloid deposits, granulomas, iron, eosinophilic infiltrates)

Clinical Features

  • Dyspnoea, fatigue, signs of right-sided failure (elevated JVP, peripheral oedema, ascites)
  • Heart sounds may be normal; S3/S4 gallop
  • ECG: Low voltage (especially in amyloid), conduction abnormalities
  • Echo: Normal or mildly reduced systolic function, biatrial enlargement, diastolic dysfunction
  • Key distinction from constrictive pericarditis (can be clinically identical — requires cardiac catheterisation or CMR)

Congo Red Staining in Amyloidosis

  • Amyloid deposits stain orange-red with Congo red; show apple-green birefringence under polarised light

5. Stress (Takotsubo) Cardiomyopathy

Definition

Transient LV dysfunction, characterised by apical ballooning and basal hypercontractility, typically triggered by emotional or physical stress. Also known as "broken heart syndrome," "apical ballooning syndrome," or "ampulla cardiomyopathy."

Epidemiology

  • Accounts for ~4% of patients presenting with presumed ACS
  • ~90% female, predominantly postmenopausal (prevalence 5.9–7.5% in women presenting with ACS)

Pathogenesis

  • Trigger: Acute emotional/physical stress → massive catecholamine surge
  • Catecholamines cause direct myocardial toxicity (catecholamine-mediated microvascular spasm) or bind β-receptors in the apex (which has higher β-receptor density) → apical stunning
  • The 4th Universal Definition of MI does not classify Takotsubo as AMI — it is recognised as a separate syndrome, not MINOCA

Morphology / Findings

  • LV apical ballooning (akinesis/dyskinesis of apex + mid-ventricle)
  • Hypercontractile LV base
  • On CMR: transient wall motion abnormality; can show mid-wall fibrosis in some cases
  • Gross pathology: Non-specific; no permanent structural damage in typical cases

Clinical Features

  • Presents identically to STEMI: chest pain, ST elevation/T-wave changes, mild troponin rise
  • Precipitated by sudden emotional shock (grief, fear, anger) or physical stressor (surgery, stroke, sepsis)
  • Coronary angiography: No obstructive CAD (key distinguishing feature)
  • Usually reversible — LV function recovers within weeks

Prognosis & Complications

  • Not purely benign: in-hospital mortality 4.1%, long-term (1-year) mortality 5.6% (InterTAK Registry)
  • Recurrence in 5–10%
  • Complications: Acute heart failure, LV outflow obstruction (due to basal hypercontractility), cardiogenic shock, ventricular arrhythmias, LV thrombus, mitral regurgitation

Management

  • Supportive care; treat precipitant
  • ACE-I — observational benefit; improved 1-year survival
  • Beta-blockers — no proven benefit for index event or prevention of recurrence
  • No randomised controlled trials guide therapy

Quick Comparison Table

FeatureDCMARVCHCMRCMTakotsubo
LV wallThinned, dilatedNormal LV (RV affected)Thickened, non-dilatedNormal/slightly enlargedApical akinesis
Systolic fn↓↓ (EF <40%)RV failurePreserved/hyperdynamicMildly ↓Transient ↓ (apex)
Diastolic fnNormal/mildly ↓Normal↓↓↓↓Transient ↓
GeneticsLoss-of-function (TTN, MYH7, LMNA)Desmosomal proteins (plakoglobin)Gain-of-function (MYH7, MYBPC3, TNNT2)Variable (ATTR amyloid)None
Key microMyocyte hypertrophy + fibrosisFibrofatty RV replacementMyocyte disarray + fibrosisInterstitial fibrosis + specific depositsNon-specific (transient)
SCD riskYes (VF)High (athletes)High — #1 in athletes <35 yrLowLow
Key complicationCHF, embolismSCD, RV failureSCD, AF, endocarditisCHF, AFReversible; ACS mimic
MurmurMR (functional)NoneHarsh systolic ejectionNoneDynamic LVOTO possible

Key Pathology Pearls for Exams

  1. DCM vs HCM genetics: Both can involve β-MHC and troponin T mutations — but DCM = loss of function; HCM = gain of function
  2. HCM hallmark histo: Myocyte disarray — random, haphazard orientation of myofibers with bizarre branching
  3. ARVC hallmark histo: Fibrofatty replacement of RV wall (Masson trichrome: blue fibrosis + white fat replacing red myocardium)
  4. RCM with Congo red stain → apple-green birefringence = amyloid
  5. Endomyocardial fibrosis = most common RCM worldwide (tropical areas); Loeffler = eosinophilia-associated
  6. Takotsubo = no obstructive CAD on angiography + stress trigger + women 90% + reversible
  7. Titin (TTN) = most common single gene mutated in DCM
  8. MYH7 (β-myosin heavy chain) = most common gene mutated in HCM
  9. ARVC = desmosomal protein mutations — avoid strenuous exercise; SCD risk in athletes
  10. "Banana-shaped" LV lumen = HCM with ASH
  11. Atrial dilation without ventricular dilation = hallmark gross finding in RCM
  12. Mural thrombus at LV apex = DCM (due to stasis in dilated poorly contractile ventricle)

Sources: Robbins & Kumar Basic Pathology — pp. 371–375 (Table 9.5, Figs 9.25–9.27) | Goldman-Cecil Medicine — Chapter 47 | Braunwald's Heart Disease — Chapter on Sex Differences in CVD | Robbins Cotran & Kumar Pathologic Basis of Disease — p. 533
This is a shared conversation. Sign in to Orris to start your own chat.